[go: up one dir, main page]

SI1257648T2 - Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein - Google Patents

Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein

Info

Publication number
SI1257648T2
SI1257648T2 SI200130847A SI200130847A SI1257648T2 SI 1257648 T2 SI1257648 T2 SI 1257648T2 SI 200130847 A SI200130847 A SI 200130847A SI 200130847 A SI200130847 A SI 200130847A SI 1257648 T2 SI1257648 T2 SI 1257648T2
Authority
SI
Slovenia
Prior art keywords
osteoprotegerin
binding protein
antagonistic
binding agents
agents
Prior art date
Application number
SI200130847A
Other languages
English (en)
Inventor
Rajendra V. Deshpande
Anna Hitz
William J. Boyle
John Kevin Sullivan
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27057130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1257648(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/791,153 external-priority patent/US20030103978A1/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI1257648T2 publication Critical patent/SI1257648T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200130847A 2000-02-23 2001-02-23 Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein SI1257648T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51113900A 2000-02-23 2000-02-23
US09/791,153 US20030103978A1 (en) 2000-02-23 2001-02-22 Selective binding agents of osteoprotegerin binding protein
PCT/US2001/005973 WO2001062932A1 (en) 2000-02-23 2001-02-23 Antagonistic selective binding agents of osteoprotegerin binding protein
EP01911158.2A EP1257648B2 (en) 2000-02-23 2001-02-23 Antagonistic selective binding agents of osteoprotegerin binding protein

Publications (1)

Publication Number Publication Date
SI1257648T2 true SI1257648T2 (sl) 2016-11-30

Family

ID=27057130

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130847A SI1257648T2 (sl) 2000-02-23 2001-02-23 Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein

Country Status (9)

Country Link
EP (1) EP1257648B2 (sl)
JP (1) JP4401613B2 (sl)
AU (1) AU3868001A (sl)
CA (1) CA2400929C (sl)
DE (1) DE60134459D1 (sl)
DK (1) DK2105449T3 (sl)
MX (1) MXPA02008144A (sl)
SI (1) SI1257648T2 (sl)
WO (1) WO2001062932A1 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
DE60129254T2 (de) 2000-09-22 2008-03-13 Immunex Corp., Thousand Oaks Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
ES2706902T3 (es) † 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
CA2491669A1 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency HUMAN ANTI-HUMAN INTERLEUKIN-18 ANTIBODY, FRAGMENT AND METHOD FOR THEIR USE
EP1631315B1 (en) 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5902367B2 (ja) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
CN105555291B (zh) 2013-08-07 2021-08-24 助育公司 用于治疗雄性不育症的抗体、化合物及其衍生物
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2024044622A1 (en) 2022-08-24 2024-02-29 Amgen Inc. Anti-drug antibody assays

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69738811D1 (de) † 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
WO1998028424A2 (en) † 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
NZ332995A (en) † 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
BR9808545A (pt) † 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
WO2001062932A1 (en) 2001-08-30
DE60134459D1 (de) 2008-07-31
MXPA02008144A (es) 2002-11-29
EP1257648B2 (en) 2016-09-14
CA2400929A1 (en) 2001-08-30
AU3868001A (en) 2001-09-03
CA2400929C (en) 2011-05-31
JP4401613B2 (ja) 2010-01-20
EP1257648A1 (en) 2002-11-20
DK2105449T3 (da) 2019-10-07
EP1257648B1 (en) 2008-06-18
JP2003523772A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
AU3868001A (en) Antagonistic selective binding agents of osteoprotegerin binding protein
GB0001704D0 (en) Protein
GB0118662D0 (en) Binding agents
GB2363789B (en) Protein skimmer
EP1368654A4 (en) MULTIPLEX PROTEIN CHANGING PROVISIONS BY GLUTATHION GST BINDING
GB0003079D0 (en) Novel protein
GB0011185D0 (en) Protein
GB0024446D0 (en) Protein
GB0027905D0 (en) New protein
GB0009181D0 (en) Protein
GB0025677D0 (en) New protein
IL150774A0 (en) Apoptin-associating protein
GB0119929D0 (en) Protein
GB0008549D0 (en) Protein
AU2002357800A8 (en) Multiple binding moiety chromatography device, methods of using and methods of making same
GB0001700D0 (en) Novel protein
AU2001251558A8 (en) Clasp-1 transmembrane protein
GB0011056D0 (en) Protein
GB0008774D0 (en) Protein
GB0030186D0 (en) Protein
GB0001709D0 (en) Protein
GB0014825D0 (en) Protein
GB0015307D0 (en) Protein
GB0001708D0 (en) Protein
GB0031341D0 (en) Protein